Iqvia (NYSE:IQV) had its target price lifted by Robert W. Baird from $172.00 to $181.00 in a research note released on Thursday morning, BenzingaRatingsTable reports. They currently have an outperform rating on the medical research company’s stock.

IQV has been the topic of a number of other research reports. ValuEngine downgraded shares of Iqvia from a hold rating to a sell rating in a research report on Tuesday, February 4th. Stifel Nicolaus boosted their price target on shares of Iqvia from to and gave the stock a buy rating in a research report on Wednesday. Credit Suisse Group restated a buy rating and issued a $170.00 price target on shares of Iqvia in a research report on Friday, December 20th. Citigroup boosted their price target on shares of Iqvia from $185.00 to $195.00 and gave the stock a buy rating in a research report on Thursday. Finally, Cfra upgraded shares of Iqvia from a hold rating to a buy rating and boosted their price target for the stock from $148.00 to $185.00 in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have given a buy rating to the company. Iqvia currently has a consensus rating of Buy and a consensus price target of $174.30.

Shares of NYSE IQV traded down $1.47 during midday trading on Thursday, reaching $164.32. The stock had a trading volume of 2,962,308 shares, compared to its average volume of 1,312,776. The firm has a market cap of $31.03 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91. Iqvia has a twelve month low of $130.77 and a twelve month high of $169.14. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.12 and a current ratio of 1.12. The company’s 50 day moving average price is $158.20 and its 200 day moving average price is $151.72.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The firm had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.50 EPS. Equities analysts forecast that Iqvia will post 5.9 earnings per share for the current fiscal year.

In related news, Director Michael J. Evanisko sold 6,250 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $160.76, for a total transaction of $1,004,750.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Michael R. Mcdonnell sold 12,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the transaction, the chief financial officer now owns 14,366 shares in the company, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. Insiders have sold a total of 37,000 shares of company stock worth $5,830,215 in the last quarter. 6.00% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Iqvia by 9.3% during the 2nd quarter. BlackRock Inc. now owns 13,436,830 shares of the medical research company’s stock valued at $2,161,986,000 after purchasing an additional 1,146,138 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in Iqvia by 8.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 2,230 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 180 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Iqvia by 27.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 24,842 shares of the medical research company’s stock valued at $3,710,000 after purchasing an additional 5,294 shares in the last quarter. Massey Quick Simon & CO. LLC bought a new stake in Iqvia during the 3rd quarter valued at $43,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Iqvia during the 3rd quarter valued at $215,000. Institutional investors own 89.93% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: Monthly Dividend Stocks Can Provide Solid Income

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.